Analyst Price Target is $500.00
▲ +42,272.88% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Panbela Therapeutics in the last 3 months. The average price target is $500.00, with a high forecast of $500.00 and a low forecast of $500.00. The average price target represents a 42,272.88% upside from the last price of $1.18.
Current Consensus is
The current consensus among 3 investment analysts is to buy stock in Panbela Therapeutics. This Buy consensus rating has held steady for over two years.
Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, together with its subsidiaries, develops disruptive therapeutics for the treatment of patients with urgent unmet medical needs. The company's lead product candidates are Ivospemin (SBP-101), which has completed Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma; FlynpoviTM, a combination of eflornithine (CPP-1X) and sulindac which is in Phase III clinical trials; and Eflornithine, an enzyme-activated irreversible inhibitor of the enzyme ornithine decarboxylase. It has a research agreement with the Johns Hopkins University School of Medicine for the development of Panbela's investigative agent ivospemin. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota.